Enterprise Value
763.2B
Cash
2.652B
Avg Qtr Burn
N/A
Short % of Float
0.70%
Insider Ownership
0.15%
Institutional Own.
83.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Kisunla (Donanemab) Details Alzheimer's disease | Approved Quarterly sales | |
Jaypirca® Pirtobrutinib Details Cancer, Chronic lymphocytic leukemia, Lymphoma, Blood cancer, Small lymphocytic lymphoma | Approved Quarterly sales | |
Jaypirca (pirtobrutinib) Details Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma | Approved Quarterly sales | |
Omvoh™ (mirikizumab-mrkz) Details Ulcerative colitis | Approved Quarterly sales | |
Zepbound (Tirzepatide) Details Obesity | Approved Quarterly sales | |
Jardiance® (empagliflozin) (anti-SGLT2) Details Diabetes, Type 2 diabetes, Chronic kidney disease | Approved Quarterly sales | |
Lebrikizumab Details Skin disease/disorder, Atopic dermatitis | BLA FDA meeting | |
Retevmo +/- pembrolizumab Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Abemaciclib Details Castration-resistant prostate cancer | Phase 3 Data readout | |
Emgality® (galcanezumab-gnlm) Details Migraines | Phase 3 Data readout | |
Remternetug Details Alzheimer's disease | Phase 3 Data readout | |
Mirikizumab Details Crohns disease | Phase 3 Update | |
Pirtobrutinib Details Cancer, Blood cancer, Lymphoma, Chronic lymphocytic leukemia | Phase 3 Update | |
Orforglipron Details Obesity | Phase 3 Update | |
Tirzepatide Details Obstructive sleep apnea , Sleeping disorder | Phase 3 Update | |
Retevmo Details Medullary Thyroid Cancer | Phase 3 Update | |
Orforglipron Details Type 1 diabetes | Phase 3 Update | |
Verzenio® (Abemaciclib ) Details Breast cancer, Cancer | Phase 3 Update | |
Retatrutide Details Obesity | Phase 3 Initiation | |
Phase 2b Update | ||
Tirzepatide Details metabolic dysfunction-associated steatohepatitis , Liver fibrosis | Phase 2 Update | |
Peresolimab /LY3462817 Details Autoimmune disease, Rheumatoid arthritis | Phase 2 Update | |
Mirikizumab (Pediatric) Details Ulcerative colitis | Phase 2 Update | |
Olomorasib +/- KEYTRUDA® (pembrolizumab) Details Cancer, Solid tumor/s | Phase 1/2 Update | |
DC-853 Details Inflammatory disease, Autoimmune disease | Phase 1 Update | |
AK-OTOF Details OTOF-mediated hearing loss | Phase 1 Update |